stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+2 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
0.00 | — | 0.00 | 66.60 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(2.08) | — | (10.09) | (37.34) | |
P/B ratio |
0.00 | — | 1.58 | 4.74 | |
Price to Tangible BV |
0.00 | — | 1.58 | 4.74 | |
EV/Sales |
0.00 | — | 0.00 | 52.56 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(0.47) | — | (0.77) | (4.40) | |
EV/FCF |
(0.46) | — | (0.91) | (3.11) | |
Quick Ratio |
— | 2.70 | 8.85 | 8.08 | |
Current Ratio |
— | 2.85 | 9.17 | 8.30 | |
Net Debt/EBITDA |
0.00 | 0.00 | 8.44 | 6.63 | |
Debt/Assets |
0.00% | 0.88% | 0.35% | 0.24% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | 0.00 | 0.12 | |
Operating CF/Net income |
0.76 | 0.00 | 1.16 | 0.86 | |
Capex/Depreciation |
(60.86) | (0.34) | 19.58 | (23.24) | |
Interest Coverage |
(195.93) | — | (352.26) | (462.03) | |
Research and Development Expense of Revenue |
589.68% | — | 800.28% | 1,018.85% | |
Selling, General and Administrative Expense of Revenue |
104.10% | — | 187.21% | 215.36% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
54.17% | — | 88.52% | 130.47% | |
Graham Net Nets |
(1.71) | — | 0.52 | 0.17 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(30.53%) | — | (30.53%) | (30.53%) | |
Free Cash Flow Yield |
(102.57%) | — | (40.22%) | (25.41%) | |
Revenue per Share |
0.31 | — | 0.11 | 0.05 | |
Operating CF per Share |
(1.48) | 0.00 | (1.24) | (0.45) | |
Capex per Share |
(4.66) | 0.00 | 0.94 | (0.51) | |
Free Cash Flow per Share |
(6.14) | 0.00 | (0.30) | (0.97) | |
Cash per Share |
0.00 | 0.00 | 7.96 | 3.57 | |
Shareholders Equity per Share |
0.00 | 0.00 | 7.94 | 3.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 7.94 | 3.56 | |
Free Cash Flow |
(202.54) | (204.13) | (19.17) | (123.88) | |
Working Capital |
— | 152.16 | 477.00 | 413.62 | |
Capital Expenditures |
(153.79) | (3.51) | 61.22 | (65.93) | |
Net Current Asset Value |
0.00 | (711.78) | 424.45 | 364.61 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
15.18 | 0.00 | (8.47) | 10.44 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
— | — | 572.00 | 280.85 |
Columns are period end dates · fundamentals updated 26 Oct 2026